Related Experiment Video
Updated: Jun 18, 2026

12:55
P50 Sensory Gating in Infants
Published on: December 26, 2013
Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study
Merilyne C Waldo1, Laurie Woodward, Lawrence E Adler
1The Denver VAMC VISN19/MIRECC and UC Denver, School of Medicine, Department of Psychiatry, CO 80220, USA. merilyne.waldo@va.gov
Psychiatry Research
|December 5, 2009
Abstract
None:
Most schizophrenic patients have a deficit in auditory sensory gating that appears to be mediated by the alpha-7 nicotinic receptor. This pilot study examines the effects of varenicline, an alpha-7 agonist, on the P50 auditory evoked potential in six schizophrenic patients. The study was canceled because of concerning side effects consistent with those reported by the FDA. However, in this small group of subjects, varenicline did not consistently enhance P50 auditory gating.

